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Background: The ideal goal of clinical therapy in periodontal defects is regeneration of all lost structures. For
regeneration tooccur, cellproliferation,migration,andextracellularmatrix synthesisareprerequisites.Attempts
at regeneration of periodontal defects by guided tissue regeneration using bone grafts and membranes have not
always yielded predictable results. Recently, attempts at engineering the defects using various materials have
shown promising results. Two such approaches have been used to regenerate periodontal defects, one using ex-
tracellularmatrix suchasenamelmatrixproteinsand theotherusinggrowth factors.However, toourknowledge,
no study has looked at combining these two approaches to achieve potentially even greater regeneration.
Methods: Primary human periodontal ligament (PDL) fibroblasts were explanted, and alkaline phosphatase
(ALK PHOS) activity was determined. Phenotypically different cell lines were incubated for 1, 3, 6, and 10 days
in 0.2% fetal bovine serum (FBS) media containing different concentrations of either enamel matrix derivative
(EMD), amelogenin, platelet-derived growth factor-BB (PDGF-BB), EMD + PDGF-BB, or amelogenin + PDGF-
BB. A culture of 0.2% FBS alone served as a negative control, and a culture of 10% FBS served as a positive
control. Cell proliferation was measured using a Coulter counter to determine the cell number. The effects on
a wound-fill model were evaluated by scraping a 3-mm wide cell-free zone in PDL monolayers across the diam-
eter of the tissue-culture plate and determining PDL cellmigration into the cell-free zoneusing computer assisted
histomorphometry.
Results: Compared to the control, only EMD + PDGF-BB significantly increased PDL cell proliferation in an
ALK PHOS (-) cell line (P <0.001), and EMD alone, EMD + PDGF-BB, and amelogenin + PDGF-BB signifi-
cantly increased PDL cell proliferation in an ALK PHOS (+) cell line (P <0.001) with EMD + PDGF-BB showing
a trend for greater proliferation than either PDGF or EMD alone. Individually, EMD and amelogenin had no
significant effect on PDL cell proliferation. In the wound-fill experiment, all factors and their combinations ex-
cept amelogenin significantly enhanced cell migration compared to the control (P <0.05) at the wound edge.
In addition, EMD + PDGF-BB had additive effects on the ALK PHOS (-) cell line at the wound edge. At the cen-
ter of the wound, neither EMD nor amelogenin had a significant wound-fill effect. However, the combination of
EMD + PDGF-BB additively increased wound fill for both ALK PHOS (+) and ALK PHOS (-) cells.
Conclusions: The combination of EMD and PDGF-BB produces greater proliferative and wound-fill effects
on PDL cells than each by themselves. If these combined effects can be translated clinically, one may see
greater regeneration in periodontal defects with this combination. However, amelogenin does not have signif-
icant effects on PDL cell proliferation or migration by itself. This may suggest that either another enamel ma-
trix component in EMD may be responsible for some of its clinical effects, or that amelogenin alone may not
trigger the regenerative potential of periodontal tissues and that it requires a combined interaction with other
enamel matrix components of EMD to direct the regenerative process. J Periodontol 2006;77:1242-1252.
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E
namel matrix derivative (EMD) is a freeze-dried
enamel matrix protein extract or gel derived
from developing tooth buds of 6-month-old
piglets. Its treatment rationale is based on the obser-
vation that initiation of acellular cementum is regu-
lated by the inner enamel epithelium of Hertwig’s
epithelial root sheath (HERS).1 Also, the proteins
found in acellular cementum have been shown to
resemble enamel matrix proteins.2 Histologically,
EMD applied to root surfaces has been shown to
produce regeneration through the formation of bone,
periodontal ligament (PDL), and acellular cemen-
tum.3 Others have observed regeneration with ce-
mentum that was mostly cellular rather than acellular,4
and regeneration was not always consistent.5
Clinically, EMD has shown very promising results.
In early human trials, EMD demonstrated an ability to
enhance regeneration when applied in conjunction
with periodontal surgery.6 The clinical effects of
EMD were compared to other treatment modalities
and showed similar, if not better, clinical results. Hejil
et al.7 compared the effects of EMD versus modified
Widman flap (MWF) in mostly 1- and 2-wall defects
and found that EMD-treated sites had 2.6 mm radio-
graphic bone gain, whereas the MWF sites did not
show improvement from baseline. Froum et al.8 also
compared the effects of EMD in periodontal defects
compared to MWF alone and showed superior defect
fill with EMD at reentry. In horizontal defects, EMD in
conjunction with open-flap debridement maintained
the attachment level, whereas debridement alone
showed a significant loss of attachment.9 Compared
to guided tissue regeneration (GTR), EMD generally
showed comparable results in attachment gain in in-
trabony defects.10,11 In addition to intrabony defects,
EMD used in conjunction with coronally advanced
flaps in recession defects resulted in root coverage
similar to coronally advanced flap with subepithelial
connective tissue, and one histologic specimen
even showed regeneration of cementum, bone, and
PDL.12,13 When the long-term clinical results of
EMD were assessed, Sculean et al.14 found that the
clinical improvements obtained with EMD can be
maintained over a 4-year period.
Clinical reports continue to support EMD as a re-
generative material in periodontal defects, but the
mechanism of regeneration achieved by EMD is
largely unknown.15 EMD has been shown to selec-
tively enhance the proliferation of PDL cells, but not
of epithelial cells.16 Kawase et al.17 have also shown
EMD’s effect as a cytostatic agent against epithelial
cells, thus suppressing the downgrowth of junctional
epithelium onto root surfaces. EMD’s effect on bone
formation suggests osteopromotive rather than os-
teoinductive potential. Boyan et al.18 placed demin-
eralized freeze-dried bone allograft (DFDBA) in
combination with EMD in mouse calf muscle and
found enhanced bone induction compared to DFDBA
alone. In vitro experiments19 using osteosarcoma
cells showed that EMD can stimulate proliferation
and differentiation of osteoblasts depending on their
state of maturation. EMD has also been suggested
to upregulate intracellular cyclic adenosine mono-
phosphate (cAMP) levels and to enhance secretion
of transforming growth factor-beta (TGF-b) and inter-
leukin-6 (IL-6).19-21 van der Pauw et al.21 observed
that EMD increased alkaline phosphatase (ALK
PHOS) and subsequent stimulation of PDL attach-
ment but not proliferation.
The idea that EMD mimics the primary formation of
roots and their supporting structures is currently un-
der debate. The majority of EMD is 90% amelogenin,
and the remaining 10% is primarily proline-rich non-
amelogenins, tuftelin, tuft protein, enamelin, and se-
rum proteins. Enamel proteins are not shown to be
present in the region of acellular cementum growth
during root development but only in the apical portion
of the root.22 Recently, amelogenin has been found to
be absent along the developing root surfaces of
mouse molars.23 Although EMD clearly shows poten-
tial for stimulating regeneration, as mentioned above,
the mechanism of action of EMD is not well under-
stood, and its interaction with other growth factors
and proteins in the periodontal wound site needs to
be studied further.
Amelogenin is an enamel matrix protein ;25 kDa
produced by epithelial-derived ameloblasts. This pro-
tein is rapidly degraded to a more stable form ;20
kDa. Structurally, recombinant amelogenin forms
spheres of about 100 molecules, measuring 20 nm
in diameter. This corresponds to the spacing between
developing enamel crystallites, suggesting the role of
amelogenin in the structural framework of enamel
during development.24,25 Recently, leucine-rich amelo-
genin peptides have been shown to have a direct effect
on cementoblast activity.26 As the major component of
EMD, amelogenin may contribute significantly to the
observed biologic effects of EMD.
Platelet-derived growth factor (PDGF) is a dimeric
molecule of A and B and recently discovered C and D
chains. It is secreted primarily by the a-granules of
platelets, but activated macrophages and fibroblasts
produce it as well. PDGF, in concert with other growth
factors, is an important mediator of wound healing.
PDGF stimulates cells by binding to a- and b-recep-
tors found on cell surfaces. The a-receptors can bind
both A and B chains, but the b-receptors can only bind
to B chains. Lynch27 first discovered that PDGF can
promote regeneration of bone, cementum, and peri-
odontal ligament. Studies have shown that PDGF-BB
is more effective in mitogenesis and chemotaxis
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compared to either AA or AB.28 The addition of
PDGF-BB has been shown to improve both migration
and proliferation of cells in the periodontium.29-35 In
cultures of quiescent PDL cells, PDGF-BB stimulates
the PDL-fibroblast cells to divide without the addition
of other factors.36 Mumford et al.,37 using an in vitro
wound model to investigate PDL and gingival fibro-
blasts, found that wound fill by PDL cells significantly
increased with the addition of PDGF-BB. The com-
bination of PDGF-BB and insulin-like growth factor
has been shown to have synergistic effects on the
regeneration of defects in animals.38-40 Matsuda
et al.31 have shown that recombinant human PDGF
(rhPDGF) can stimulate collagen synthesis by PDL
cells. Interestingly, cultured human PDL cells exposed
to EMD showed increased production of PDGF-AB.20
More recently, Papadopoulos et al.41 have shown that
PDGF-BB in combination with bone allografts syner-
gistically stimulated PDL proliferation in vitro, and
Nevins et al.42 and Camelo et al.43 have shown histo-
logic regeneration in Class II furcation defects by us-
ing rhPDGF-BB and bone allograft in humans. These
findings support an important role of PDGF-BB in the
regeneration of the periodontal wound.
Two different types of molecules have been studied
individually for tissue regeneration; one type are ex-
tracellular matrix proteins and the other type are
growth factors. In natural wound healing, both of these
types of molecules are important. Thus, it is plausible
to combine EMD and PDGF-BB in a wound model to
attempt an even greater regenerative potential than
each has by itself. Therefore, the objective of the pres-
ent investigation was to evaluate the effects of EMD,
PDGF-BB, and amelogenin individually and in combi-




All tissue samples were obtained from healthy pa-
tients ranging in age from 25 to 55 years and without
periodontal disease following guidelines established by
the Institutional Review Board of the University of
Texas Health Science Center at San Antonio. All tis-
sue samples were handled using an aseptic technique
and directly placed in 50-ml tissue culture tubes con-
taining Dulbecco’s modified Eagle’s medium (DMEM)
containing 1% penicillin/streptomycin, 1% fungizone,
and 10% fetal calf serum. Remaining procedures were
conducted in a sterile environment under a laminar-
flow hood.
Primary human PDL cell lines were cultivated from
thin layers of PDL tissues attached to the middle one-
third of extracted premolar and molar tooth roots.
Using sharp sterile blades, PDL tissue fragments were
removed from each tooth and placed in 60-ml tissue-
culture plastic plates containing 4 ml DMEM contain-
ing 4,500 mg/L D-glucose, 1% penicillin/streptomy-
cin, 1% fungizone, and 10% fetal calf serum. A small
piece of stainless steel wire grid was placed on top
of the fragments to prevent movement of explants
and to promote the outgrowth of new cells. Within 3
weeks, ;40% PDL explants were successfully forming
primary cultures with a sufficient number of new cells.
The wire grid was removed from the plate to permit
more new cell growth. PDL cells were maintained at
37C in humidified air containing 5% CO2 and 95%
air. Upon reaching confluence, cells were removed
by incubation with 0.25% trypsin and passaged to
100-ml tissue culture plates. Four cell lines from four
different individuals were used at passages four to
nine.
Alkaline Phosphatase Assay
Alkaline phosphatase activity for individual cell lines
was determined using cell monolayers. A T-75 flask of
PDL cells was trypsinized and resuspended in culture
medium at a cell density of 18,800 cells/ml. One mil-
liliter of the cell suspension was placed into each of the
12 wells (10,000 cells/cm2) on two 24-well culture
plates. The cells were cultured to confluence at
37C in a 5% CO2:95% air. One plate was subjected
to histochemical staining using an alkaline phospha-
tase conjugate substrate kit¶ following the manufac-
turer’s instructions. The resultant staining was
photographed at ·100 magnification. The media
was removed from the wells on the second plate,
and the cells were washed twice with phosphate buff-
ered saline. After addition of 0.01% Triton X-100 lysis
buffer, the plates were sealed with parafilm and placed
at -80C. The cells were thawed and refrozen three
times to break open the cells. The liquid and cells were
transferred to labeled microfuge tubes and stored fro-
zen until the assay was performed. Cells were cen-
trifuged prior to the assay to remove debris. The
supernatant was used for the assay. The assay solu-
tions were as follows: 1) 1.5 M (6.68 g/50 ml)
2-amino-2-methyl-1-propanol (2A2MIP), pH 10.25
(titrated with HCl); 2) 20 mM pnpp (5.26 mg/ml);
and 3) 10 mM MgCl2. The working reagent contained
one part solution 1 plus one part solution 2 plus one
part solution 3. The stop solution was 1N NaOH. Stan-
dards were prepared in the same buffer as the sam-
ples. Using 96-well plates, 50 ml of each standard
solution in duplicate was pipetted into wells of the first
two columns, 50 ml of buffer in duplicate served as the
blank, and 50 ml of each sample was pipetted in dupli-
cate in the remaining wells. A total of 50 ml prepared
working reagent was added to each well and incu-
bated at 37C for 1 hour. The reaction was stopped
with the addition of 100 ml/well of 1N NaOH. The
¶ Catalog number 170-6432, Bio-Rad, Hercules, CA.
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optical density of each well was determined using a
plate reader# at 405 nm.
Protein was determined on the same samples using
the bicinchoninic acid (BCA) procedure.** Standards
were prepared using the stock solution of 1 mg/ml of
bovine serum albumin (BSA) supplied with the kit.
The working reagent consisted of 50 parts reagent
A and one part reagent B. A total of 10 ml buffer blank,
and 10 ml of each standard and sample were pipetted
in duplicate into the wells of a 96-well plate. A total of
200 ml BCA working reagent was added to each well,
and the plates were incubated at 37C for 30 minutes.
The optical density of each well was determined using
a plate reader†† at 562 nm. Alkaline phosphatase-
specific activity was calculated for each sample and
expressed as nmol/mg protein. The data were ex-
pressed as the mean – SEM (N = 12) for each PDL cell
type.
Cell Proliferation Assay
Tissue-culture plates (24-well) were seeded with PDL
cells using 1 · 104 cells per well in 1 ml DMEM con-
taining 10% fetal bovine serum (FBS). The culture
plates were incubated at 37C in humidified air with
5% CO2 for 6 hours. The media was removed and re-
placed with DMEM alone for 24 hours, allowing the
cells to become quiescent. DMEM was removed,
and the desired concentrations of EMD,‡‡ PDGF-
BB, amelogenin, or different combinations of either
EMD and PDGF-BB or amelogenin and PDGF-BB
were added in 0.2% DMEM. Control cultures consisted
of similarly plated cells in media containing 10% FBS
(positive control) or 0.2% FBS (negative control)
without the addition of proteins. The concentrations
of individual factors used were 50, 150, and 250
mg/ml EMD; 50 and 250 mg/ml recombinant amelo-
genin protein (rpAmel); and 20, 50, and 100 ng/ml
PDGF-BB. All possible combinations of EMD and
PDGF-BB and combinations of amelogenin and
PDGF-BB concentrations were also added. At appro-
priate time points (1, 3, 6, and 10 days), trypsin was
added to each well and allowed to incubate for an ad-
ditional 5 to 10 minutes. Cell number was determined
using a Coulter counter at each of the four time points.
Each experiment was performed in triplicate using
two different cell lines of PDL fibroblasts.
In Vitro Cell-Layer Wounding
Using tissue-culture plates (six-well), PDL cells were
seeded at a concentration 5 · 104 per well. The seeded
cells were allowed to reach 90% confluence in DMEM
with 10% fetal calf serum without antibiotics and a hu-
midified atmosphere of 5% CO2 and 95% air. The cells
were then synchronized by replacing their culture
medium with DMEM without serum for 24 hours.
The experimental wound was created as previously
described by Lackler et al.44 Briefly, a sterile 3-mm
wide soft rubber policeman was used to scrape off
a 3-mm wide cell layer down the middle of the well.
The scraped cell layer was gently rinsed three times
with DMEM without serum to ensure that all cel-
lular and extracellular debris were removed from the
wound site. A long linear scratch under the well
marked both edges of the wound; these marks served
as the starting point for cells repopulating the wound
area. Treatment medium was added according to the
experimental design. Control cultures consisted of
10%FBS(positivecontrol)or0.2%FBS(negativecon-
trol) without the addition of proteins. The concentra-
tions of individual factors used were 50 and 250 mg/ml
EMD, 50 and 250 mg/ml rpAmel, and 20 and 100
ng/ml of PDGF-BB. Different combinations of EMD
and PDGF-BB and different combinations of amelo-
genin and PDGF-BB were added together as noted
in the results. Cells were treated for 1, 3, 6, and 10
days. The concentrations of EMD and PDGF-BB used
were based on preliminary experiments in our labora-
tory (data not shown) and previously published
studies.37,45 The concentration of amelogenin was
the same as the concentration of EMD, based on the
>90% amelogenin content of EMD. Effects of different
factors in both growth and wound fill were most dra-
matic at days 6 and 10. Because day-6 data showed
similar trends as day-10 data, only day-10 data are
presented for simplification of figures.
At an appropriate time point, cells were fixed with
100% ethanol and stained with crystal violet. Quanti-
fication of wound repopulation was accomplished
using a light microscope equipped with a computer-
assisted digital image analyzer.§§ Four areas of inter-
est (AOI), each having a total area of 0.75 mm2, were
analyzed (Fig. 1). AOI 1 was within the established
cell monolayer; AOI 2 was within the established
cell monolayer adjacent to the wound edge; AOI 3
was within the wound space adjacent to the wound
edge; and AOI 4 was within the wound space at the
midline of the 3-mm wound. To eliminate investigator
bias, the four specific areas of interest were randomly
selected.
Statistical Analysis
Data analysis was performed using a statistical pro-
gram.ii Within each experiment, each test group
was run in replicates of three to six depending on
the experiment. The mean and variation of the repli-
cates for each test group was determined, and the
groups within the experiment were compared using
multiple comparison analysis of variance (ANOVA).
# Titertek Multiscan Plus, Titertek, Huntsville, AL.
** Pierce, Rockford, IL.
†† Titertek Multiscan Plus, Titertek.
‡‡ Emdogain, Biora, Malmö, Sweden.
§§ Image Pro Plus, Media Cybernetics, Silver Spring, MD.
ii Statgraphics Plus 5.0, Manugistics, Rockville, MD.
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Tukey’s honest significant difference (HSD) method
was used as a post-hoc test to determine the signifi-
cance between different concentrations. The P value
was set at the 0.05 level of significance.
RESULTS
Alkaline Phosphatase Assay
The histochemical staining for alkaline phosphatase
activity in two different cell lines showed greater activ-
ity for one cell line (ALK PHOS [+]) than for the other
cell line (ALK PHOS [-]), which only showed minimal
histochemical staining (Fig. 2). Alkaline phosphatase
specific activity calculated from optical density values
once again shows greater activity for ALK PHOS (+)
and very little activity for ALK PHOS (-) (Fig. 2).
Cell Proliferation Assay
Proliferation assays showed distinct differences be-
tween the two cell lines. Proliferation data for ALK
PHOS (+) fibroblasts demonstrated no significant ef-
fects by EMD or amelogenin, but a statistically signif-
icant enhancement of PDL-fibroblast proliferation
over negative control media at day 10 was seen with
PDGF-BB at concentrations of 50 and 100ng/ml. In
addition to PDGF-BB alone, combinations of PDGF-
BB with EMD or amelogenin produced significant cell
growth at days 6 and 10. On day 10, all combinations
of EMD and PDGF-BB, except the combinations of 50
mg/ml EMD + 20 ng/ml PDGF-BB and 250 mg/ml
EMD + 20 ng/ml PDGF-BB, significantly increased
cell numbers compared to the negative control. Sim-
ilarly, the combinations of amelogenin and PDGF-BB
increased the cell number. By contrast, the prolifera-
tion assays for ALK PHOS (-) fibroblasts demon-
strated an increase in cell number over time in the
positive control, but no significant increase was noted
in cell numbers with the factors by themselves. Only
the combinations of EMD and PDGF-BB significantly
increased cell numbers at days 6 and 10 (Fig. 3). How-
ever, the combinations of amelogenin and PDGF-BB
did not show a similar increase in ALK PHOS (-) cell
proliferation. Other differences between the two cell
lines are that significant cell proliferation by PDGF-
BB and the combinations of PDGF-BB with either
EMD or amelogenin was greater than the positive con-
trol for ALK PHOS (+) cells. However, at no time did
EMD and PDGF-BB combinations show greater in-
creases in cell proliferation for the ALK PHOS (-) cell
line than the positive control.
In Vitro Cell-Layer Wounding
Wound assays for the two different cell lines of PDL fi-
broblasts demonstrated variations in the magnitude,
but similar trends were seen in both cell lines in re-
sponse to EMD, PDGF-BB, and amelogenin. In AOI
3 of the ALK PHOS (+) cell line at day 10, a
Figure 1.
In vitro cell layer wound model. AOI 1 is located within the confluent
cell layer. AOI 2 is located at the confluent cell layer edge. AOI 3 is
located at the wound edge. AOI 4 is located at the center of the
wound.
Figure 2.
Alkaline phosphatase-specific activity (A) and histochemical staining
(B). ALK PHOS (+) showed abundant alkaline phosphatase activity
by a majority of the cells in the monolayer. By contrast, ALK PHOS (-)
showed little or no alkaline phosphatase activity in the monolayer.
The results of the enzyme activity assay were consistent with the
histochemical results. Note that the alkaline phosphatase-specific
activity in the ALK PHOS (+) cells is approximately five-fold greater
than the activity in the ALK PHOS (-) cells (A). *Statistically
significant at P <0.05 compared to PDL C.
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concentration of 250 mg/ml EMD significantly in-
creased cell numbers compared to the negative
control, but the response to amelogenin was not sta-
tistically significant. Similarly, the ALK PHOS (-)
cell line responded to 50 and 250 mg/ml EMD with sig-
nificant wound fill, but wound fill with amelogenin did
not exhibit a significant wound-fill response. PDGF-
BB concentrations of 20 and 100 ng/ml showed sig-
nificant wound fill compared to the negative control
in AOI 3 of ALK PHOS (+) and ALK PHOS (-) cell lines.
When the specific factors were combined, both PDL
cell lines showed significant wound fill. All combina-
tions of EMD and PDGF-BB in both PDL cell lines were
statistically significant. In ALK PHOS (-) cells, 50
mg/ml EMD combined with PDGF-BB showed a trend
for greater wound fill at AOI 3 than 250 mg/ml EMD
combined with PDGF-BB, but it was not statistically
significant. The ALK PHOS (-) cell response to 50
mg/ml EMD + 100 ng/ml PDGF-BB showed statisti-
cally greater wound fill at AOI 3 than either 50 mg/ml
EMD or 100 ng/ml PDGF-BB alone (Fig. 4). Similar
to the EMD + PDGF-BB combination response, all
combinations of amelogenin and PDGF-BB for both
cell lines showed significant wound fill. However, in
both cell lines, the responses from combinations of
amelogenin and PDGF-BB were similar in magnitude
to PDGF-BB alone. This similar level of wound fill
achieved by PDGF-BB alone and in combination with
amelogenin suggests that the effects of
the amelogenin combination may be
solely due to the PDGF-BB effect only,
whereas EMD in combination with
PDGF seems to have an additive effect
in wound fill for ALK PHOS (-) cells.
The wound-fill response to EMD was
different at the center of the wound (AOI
4) compared to the response at the
wound edge (AOI 3). In AOI 4, neither
EMD nor amelogenin showed signif-
icant wound fill compared to the nega-
tive control in either PDL cell line,
but only PDGF-BB and combinations
of PDGF-BB with either EMD or amelo-
genin showed significant wound fill in
both PDL cell lines. In the ALK PHOS
(+) cell line, the wound-fill response to
PDGF-BB was significant on days 6
and 10. In the ALK PHOS (-) cell line,
PDGF-BB had a significant effect only
on day 10. In ALK PHOS (+) cells, 250
mg/ml EMD + 100 ng/ml PDGF-BB
showed statistically greater wound fill
than 250 mg/ml EMD alone or 100
ng/ml PDGF-BB alone (Fig. 5). In ALK
PHOS (-) cells, 50 mg/ml EMD + 20
ng/ml PDGF-BB showed statistically
greater wound fill than either 50 mg/ml EMD alone
or 20 ng/ml PDGF-BB alone (Fig. 6). Combinations
of amelogenin and PDGF-BB also showed significant
wound fill. However, the amount of wound fill with
Figure 3.
ALK PHOS (-) cell proliferation response to EMD, PDGF-BB, and
combinations of EMD + PDGF-BB. ALK PHOS (-) cells showed
statistically greater responses to the concentrations of 50 mg/ml
EMD + 100 ng/ml PDGF-BB than either 50 mg/ml EMD or
100 ng/ml PDGF-BB alone. *Statistically significant at P <0.05
compared to 0.2% FBS.
Figure 4.
ALK PHOS (-) cell wound-fill response to combinations of EMD + PDGF-BB at AOI 3
on day 10. The ALK PHOS (-) cell line showed statistically significant wound-fill responses
at AOI 3 to all combinations of EMD and PDGF-BB at day 10. Combination responses
except EMD 50 mg/ml + PDGF 20 ng/ml were no greater than the PDGF-BB response
alone. The EMD 50 mg/ml + PDGF 20 ng/ml response showed statistically greater wound
fill than the response to PDGF 20 ng/ml. *Statistically significant at P <0.05 compared to
0.2% FBS. †Statistically significant at P <0.006 compared to EMD 50 mg/ml. §Statistically
significant at P <0.006 compared to PDGF-BB 20 ng/ml.
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amelogenin and PDGF-BB combined treatment was
similar to the amount of wound fill achieved by
PDGF-BB alone (Fig. 7). This similar level of wound
fill achieved by PDGF-BB alone and in combination
with amelogenin again suggest that the effects of
amelogenin combination may be solely
due to the PDGF-BB effect only,
whereas EMD in combination with
PDGF seems to have an additive effect
on wound fill at the center of the
defect.
DISCUSSION
Periodontal wound regeneration re-
quires recruitment of connective tissue
cells to the site, proliferation of these
cells, and the synthesis of new tissue to
replace the destroyed connective tissue
component. For these processes to oc-
cur, the cells require extracellular matrix
for attachment and the local release of
cytokines to additionally signal the cells.
In recent years, the application of either
the extracellular matrix or a myriad
of growth factors in periodontal defects
to promote regeneration has received
prominent attention. However, to our
knowledge, no study to date has looked
at the combination of extracellular ma-
trix and growth factors in achieving the
regeneration of periodontal defects.
EMD has been studied extensively
and shown to promote clinical peri-
odontal regeneration. However, its
mechanism of action has yet to be de-
termined. It has been speculated that
amelogenin, the major component of
EMD, is the active component in this
process, but this has yet to be proven.
PDL fibroblasts have the capacity to
regenerate a periodontal defect with
cementum, bone, and periodontal liga-
ment by differentiating into cells of
cementogenic, osteogenic, and fibro-
blastic lineage.46,47 Carnes et al.48 were
able to isolate fibroblasts with osteo-
genic characteristics compared to cells
with fibroblasic characteristics using
the expression of alkaline phosphatase
activity and osteocalcin release. Fibro-
blasts that produced high alkaline phos-
phatase typically formed mineralized
matrix.48 Thus, different phenotypes
of PDL fibroblasts can be isolated and
may respond differently to attempts at
regeneration through biomimetics and
may explain the seemingly contradictory results in
published studies regarding the in vitro effects of
EMD.
In this study, two different cell types were charac-
terized, and their response to EMD, PDGF-BB, and
Figure 5.
ALK PHOS (+) cell wound-fill response to combinations of EMD + PDGF-BB at AOI 4 on
day 10. The ALK PHOS (+) cell line showed statistically greater wound fill compared to
negative control at AOI 4 to all combinations of EMD and PDGF-BB at day 10.
Combination responses except EMD 250 mg/ml + PDGF 100 ng/ml were no greater
than the PDGF-BB response alone. The EMD 250 mg/ml + PDGF 100 ng/ml response
showed statistically greater wound fill than the response to PDGF 100 ng/ml. *Statistically
significant at P <0.05 compared to 0.2% FBS. §Statistically significant at P <0.006
compared to PDGF-BB 100 ng/ml.
Figure 6.
ALK PHOS (-) cell wound-fill response to combinations of EMD + PDGF-BB at AOI 4
on day 10. The ALK PHOS (-) cell line showed statistically significant wound fill at AOI 4
to all combinations of EMD and PDGF-BB at day 10. Combination responses except EMD
50 mg/ml + PDGF 20 ng/ml were no greater than the PDGF-BB response alone. The EMD
50 mg/ml + PDGF 20 ng/ml response showed statistically greater wound fill than the
response to PDGF 20 ng/ml. *Statistically significant at P <0.05 compared to 0.2% FBS.
§Statistically significant at P <0.006 compared to PDGF-BB 100 ng/ml.
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amelogenin were studied. Of the pri-
mary cells harvested, ALK PHOS (+)
cells showed high alkaline phospha-
tase activity, which suggests an osteo-
blastic phenotype, whereas the lack of
alkaline phosphatase activity of ALK
PHOS (-) cells was more typical of fi-
broblasts. Accordingly, each primary
PDL cell line gave different results for
proliferation. The results from the pro-
liferation assay of the ALK PHOS (+)
cell line showed that PDGF-BB and
the combinations of PDGF-BB with
EMD or amelogenin produced signif-
icantly greater responses than the neg-
ative control. In the ALK PHOS (-)
cell line, PDGF-BB did not have a sta-
tistically significant effect, and only
the combination therapy of EMD
and PDGF-BB produced significantly
greater proliferative responses. Sur-
prisingly, neither EMD nor amelogenin
had statistically significant effects in ei-
ther cell line. The difference in proliferative results
suggests that different cell phenotypes respond differ-
ently in the presence of extracellular matrix and cyto-
kines. More specifically, PDGF-BB elicited significant
proliferative responses mainly in alkaline phospha-
tase positive cells. In ALK PHOS (-) PDL fibroblasts,
EMD enhanced the PDGF-BB response to produce
significantly greater proliferation (Table 1).
A possible explanation for this enhanced PDGF-BB
response in combination with EMD may be attributed
to the binding properties of the fibroblasts to the extra-
cellular matrix. Fibroblast functions such as prolifera-
tion and migration are initiated by cell attachment. In
typical in vitro experiments, fibroblast viability can
be verified by microscopic examination of cell attach-
ment. Characteristic changes in morphology from a
round to elongated shape indicate fibroblast attach-
mentandsurvival. Fibroblastsattach to theextracellu-
lar matrix partly through integrin binding, and the
resultant change in the cell morphology as it attaches
to EMD may expose more PDGF-BB receptors.49
Thus, the fibroblast proliferative response may be in-
creased through greater PDGF-BB binding to receptor
sites on attached fibroblasts.
PDGF stimulates fibroblasts by binding to a- and
b-receptors found on the cell surface. The presence
of different PDGF receptors on PDL fibroblasts has
been shown to be influenced by autocrine factor pro-
duction. One such factor, TGF-b, has been implicated
in changing PDGF-BB affinity to fibroblasts. Oates
et al.33 have shown a decrease in a-receptor subunits
but increased b-receptor subunits by PDL fibroblasts
after exposure to TGF-b. This selective receptor
Figure 7.
ALK PHOS (-) cell wound-fill response to combinations of amelogenin + PDGF-BB at AOI
4 on day 10. The ALK PHOS (-) cell line showed a statistically significant wound fill at AOI
4 to all combinations of amelogenin and PDGF-BB at day 10, but the combination
responses were no greater than the response to PDGF-BB alone. *Statistically significant
at P <0.05 compared to 0.2% FBS.
Table 1.
Summary of Effects of Individual Factors
and Their Combinations on PDL Growth






EMD No effect No effect
Amelogenin No effect No effect
PDGF-BB Increase No effect
EMD + PDGF-BB Increase Increase
Amelogenin + PDGF-BB Increase No effect
Wound-fill results (AOI 3)
EMD Increase Increase
Amelogenin No effect No effect
PDGF-BB Increase Increase
EMD + PDGF-BB Increase Increase
additively
Amelogenin + PDGF-BB Increase Increase
Wound-fill results (AOI 4)
EMD No effect No effect
Amelogenin No effect No effect
PDGF-BB Increase Increase




Amelogenin + PDGF-BB Increase Increase
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expression can upregulate PDGF-BB binding to fibro-
blasts. In a recent study,20 periodontal fibroblasts in
the presence of EMD showed an increased autocrine
production of TGF-b. This increase in TGF-b may also
explain the enhanced PDGF-BB response through in-
creased b-receptors by EMD stimulated PDL fibro-
blasts. It is interesting that PDGF-BB had greater
proliferative effects on only ALK PHOS (+) cells,
whereas PDGF-BB’s proliferative effects on ALK
PHOS (-) cells required EMD to be significant.
The differences in proliferative response by ALK
PHOS (+) and ALK PHOS (-) cells were also seen at
the wound edge, but the wound-fill response by the
PDL fibroblasts was similar for both PDL cell lines at
the center of the wound. The results of the data at
the wound margin (AOI 3) showed that both cell lines
responded with significantly greater wound fill at the
wound margin in response to EMD and PDGF-BB in-
dividually, but only the ALK PHOS (-) cell line showed
an additive response to a combination of EMD and
PDGF-BB. However, this trend did not continue at
the center of the wound (AOI 4). At the center of the
wound, only PDGF-BB and PDGF-BB in combination
with EMD or amelogenin produced greater wound fill,
whereas EMD and amelogenin by themselves did not
increase wound-fill responses. However, the com-
bined EMD and PDGF-BB were additive, whereas
the amelogenin and PDGF-BB combination results
seem to be the result of the PDGF-BB response alone
(Figs. 6 and 7).
Thus, PDGF-BB consistently enhanced wound fill,
whereas EMD produced significant wound-fill effects
atcloseproximityof thewoundmarginbutwas ineffec-
tive further away from the wound margin. However,
EMD in combination with PDGF-BB additively in-
creasedwoundfillat thecenterof thewoundcompared
to EMD or PDGF-BB alone. We can speculate from the
proliferation and the wound-fill data that EMD used
alone significantly enhances wound healing only at
close proximity to the wound edge but may exert sig-
nificant effects at areas further away from the wound
edge by interacting with PDGF-BB. Also, ALK PHOS
(-) cells are more sensitive than ALK PHOS (+) cells
to the additive effects of EMD in combination with
PDGF-BB in proliferation and wound fill. These find-
ings are in agreement with in vivo study results using
a baboon model, in which EMD showed greater regen-
erativeeffects indefects<2mmcomparedto largerde-
fects ‡4 mm.50 Clinically, EMD enhances significantly
greaterdefectfill innarrowerdefects,and thecurrent in
vitro findings suggest limitations of EMD use alone in
wider periodontal defects. By combining EMD and
PDGF-BB in a periodontal defect, a greater defect fill
may be expected even in larger defects.
When comparing the effects of amelogenin to the
effects of EMD on the PDL fibroblasts, similar concen-
trations would have been thought to provide similar
results. This is because amelogenin composes ;90%
or more of EMD. However, amelogenin did not have
the same additive effect on PDL-fibroblast prolifera-
tion in combination with PDGF-BB as EMD had in
combination with PDGF-BB. In the wound-fill model,
EMD consistently outperformed amelogenin in PDL-
fibroblast wound fill at the wound edge, and produced
greater wound fill as an additive response with PDGF-
BB. The significant proliferation and wound healing
effects of amelogenin in combination with PDGF-BB
seem to be mostly the effects of PDGF-BB alone.
Thus, amelogenin by itself did not affect the prolifer-
ation or the migration of PDL fibroblasts, nor did it
have any additive effects in combination with PDGF-
BB. This suggests that amelogenin by itself may not
be the sole active component in EMD as commonly
assumed and that other enamel matrix proteins in
EMD, or combinations of other enamel matrix pro-
teins working in concert with amelogenin, may be re-
sponsible for the efficacy of EMD.
CONCLUSIONS
The results of these in vitro experiments validate the
clinical effects of EMD by suggesting several possible
mechanisms. First, EMD by itself has limited effects
on PDL fibroblast proliferation. However, EMD can en-
hance the proliferative effects of PDGF-BB on ALK
PHOS (+) fibroblast lineage. Second, EMD enhances
wound fill rates in ALK PHOS (+) and ALK PHOS (-)
fibroblasts, primarily near the wound edge, and addi-
tively with PDGF-BB at the center of the wound. Third,
the regenerative effects of EMD cannot be attributed
to amelogenin alone.
The results of this study propose several new con-
cepts of EMD and its effects on periodontal regenera-
tion. According to Hoang et al.,49 amelogenin in EMD
promotes cell adhesion activity. Because amelogenin
binds to hydoxyapatite, EMD may enhance attach-
ment of fibroblasts to root surfaces.49 In addition to
enhancing fibroblast attachment in a periodontal de-
fect, EMD may directly enhance proliferation of non-
mineralizing PDL fibroblasts into the defect, a crucial
aspect for enhanced periodontal ligament regenera-
tion. But even more importantly, EMD may initiate
the migration of PDL fibroblasts to the periodontal de-
fect by enhancing the affinity of the cells for PDGF-BB.
The additive effects of EMD and PDGF-BB in increas-
ing wound-fill rates in a dose-dependent manner sug-
gest a possible benefit in combining an extracellular
matrix such as EMD and a cytokine growth factor such
as PDGF-BB in a broad periodontal defect to achieve
even greater predictability in the regeneration of a lost
periodontium. Further studies combining EMD and
PDGF-BB therapy may expand the findings of this
current in vitro study to the clinic. Furthermore, and
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surprisingly, the effects of EMD on PDL fibroblasts dif-
fer greatly from the effects of its main component,
amelogenin. Amelogenin has been studied exten-
sively for its perceived effects on periodontal regener-
ation as the primary constituent of EMD, whereas
other enamel matrix protein components of EMD
are frequently overlooked in experimental designs.
The results of the current study also suggests that fu-
ture efforts in quantifying the regenerative potential of
EMD should focus more on these other enamel matrix
proteins and their combined effects with amelogenin.
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